Jaguar Health, Inc. filed with the Securities and Exchange Commission a definitive proxy statement in connection with the Company’s special meeting of…

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 8, 2026, Jaguar Health, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement (the “Proxy Statement”) in connection with the Company’s special meeting of stockholders, to be held on Novem

Original reporting
Published Oct 28, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$JAGX
Bearish
medium confidence
Mentioned
$JAGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JAGXBearishLow
01

Why it matters

The share reserve adjustment could dilute existing shareholders, influencing short‑term price action ahead of the special meeting.

02

Market read

Primary corporate action filing with modest market relevance for the stock and sector.

03

What to watch

The amendment also aligns the plan with the recent Series R preferred stock conversion, potentially improving capital structure.

Relevance 5/10Novelty 6/10Timing: ahead of the Nov 6 special meeting

Background

Jaguar Health filed a definitive proxy statement and supplemental disclosure regarding Proposal 3 to amend its 2014 Stock Incentive Plan.

Company-level read

Ticker impact

$JAGXBearishMedium confidence
Context

SEC 8‑K filing discloses a share reserve adjustment that could dilute existing shareholders if approved at the Nov 6 special meeting.

Expected impact

likely downward pressure as market prices in possible dilution

Evidence & confidence

The filing reveals a six‑fold increase in shares available for issuance, which may be viewed unfavorably by investors.

Market effects

May affect other biotech micro‑caps as investors reassess dilution risk in similar incentive plans.

Limited to U.S. over‑the‑counter biotech segment.

Minimal global impact.

Counterpoint

If the increased share reserve enables stronger employee retention, it could support long‑term growth and offset dilution concerns.

Key entities

  • Jaguar Health, Inc.

    Biotech firm filing the proxy statement.

Related articles

$JAGXMed

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

$JAGXMedAI 8/10

Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder

Jaguar Health (JAGX) announced that its drug crofelemer has shown benefits in treating intestinal failure in pediatric patients with GUCY2C gene mutation, reducing parenteral support needs. The company plans to file for FDA approval for MVID in mid-2027. Crofelemer has also shown promise in reducing parenteral support needs in patients with MVID and SBS-IF.

$JAGXMedAI 8/10

Jaguar Health unit treats infant with rare intestinal disorder

Jaguar Health Inc. (JAGX) announced its subsidiary Napo Pharmaceuticals is treating an infant with congenital sodium diarrhea using crofelemer, reducing parenteral support needs by 15%. The company plans to file a New Drug Application for microvillus inclusion disease in mid-2027, with trial data showing significant reductions in parenteral support for pediatric patients.